Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2009, Article ID 932515, 5 pages
http://dx.doi.org/10.1155/2009/932515
Clinical Study

Efficacy of Clopidrogel on Reperfusion and High-Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction

1Department of Cardiology, Faculty of Medicine, Fırat University, 23100 Elazığ, Turkey
2Cardiology Clinic, Harput State Hospital, 23110 Elazığ, Turkey

Received 2 July 2008; Revised 30 December 2008; Accepted 4 March 2009

Academic Editor: Charles Larry Campbell

Copyright © 2009 Mehmet Akbulut et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Gregorini and J. Marco, “Ticlopidine and aspirin interactions,” Heart, vol. 77, no. 1, pp. 11–12, 1997. View at Google Scholar
  2. G. J. Mishkel, F. V. Aguirre, R. W. Ligon, K. J. Rocha-Singh, and C. L. Lucore, “Clopidogrel as adjunctive antiplatelet therapy during coronary stenting,” Journal of the American College of Cardiology, vol. 34, no. 7, pp. 1884–1890, 1999. View at Publisher · View at Google Scholar
  3. M. S. Sabatine, C. P. Cannon, C. M. Gibson et al., “Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation,” The New England Journal of Medicine, vol. 352, no. 12, pp. 1179–1189, 2005. View at Publisher · View at Google Scholar · View at PubMed
  4. M. S. Sabatine, D. A. Morrow, G. Montalescot et al., “Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial,” Circulation, vol. 112, no. 25, pp. 3846–3854, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, “Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial,” The Lancet, vol. 366, no. 9497, pp. 1607–1621, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. U. Zeymer, A. K. Gitt, C. Jünger et al., “Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice,” European Heart Journal, vol. 27, no. 22, pp. 2661–2666, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. E. M. Antman, “ST-elevation myocardial infarction: management,” in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, pp. 1233–1299, Saunders/Elsevier, Philadelphia, Pa, USA, 8th edition, 2008. View at Google Scholar
  8. J. A. de Lemos, E. M. Antman, R. P. Giugliano et al., “St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy,” The American Journal of Cardiology, vol. 85, no. 3, pp. 299–304, 2000. View at Publisher · View at Google Scholar
  9. M. S. Sabatine, C. P. Cannon, C. M. Gibson et al., “Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study,” The Journal of the American Medical Association, vol. 294, no. 10, pp. 1224–1232, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. E. M. Antman, R. P. Giugliano, C. M. Gibson et al., “Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial,” Circulation, vol. 99, no. 21, pp. 2720–2732, 1999. View at Google Scholar
  11. M. J. Quinn, E. F. Plow, and E. J. Topol, “Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?,” Circulation, vol. 106, no. 3, pp. 379–385, 2002. View at Publisher · View at Google Scholar
  12. R. F. Storey, H. M. Judge, R. G. Wilcox, and S. Heptinstall, “Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin,” Thrombosis and Haemostasis, vol. 88, no. 3, pp. 488–494, 2002. View at Google Scholar
  13. U. Klinkhardt, J. Graff, and S. Harder, “Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model,” Clinical Pharmacology & Therapeutics, vol. 71, no. 3, pp. 176–185, 2002. View at Publisher · View at Google Scholar · View at PubMed
  14. D. P. Chew, D. L. Bhatt, M. A. Robbins et al., “Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein,” The American Journal of Cardiology, vol. 88, no. 6, pp. 672–674, 2001. View at Publisher · View at Google Scholar
  15. D. P. Vivekananthan, D. L. Bhatt, D. P. Chew et al., “Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention,” The American Journal of Cardiology, vol. 94, no. 3, pp. 358–360, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. M. J. Quinn, D. L. Bhatt, F. Zidar et al., “Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention,” The American Journal of Cardiology, vol. 93, no. 6, pp. 679–684, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. M. J. Davies, A. C. Thomas, P. A. Knapman, and J. R. Hangartner, “Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death,” Circulation, vol. 73, no. 3, pp. 418–427, 1986. View at Google Scholar
  18. R. J. Frink, P. A. Rooney, Jr., J. O. Trowbridge, and J. P. Rose, “Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction,” British Heart Journal, vol. 59, no. 2, pp. 196–200, 1988. View at Publisher · View at Google Scholar
  19. V. Henn, J. R. Slupsky, M. Gräfe et al., “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature, vol. 391, no. 6667, pp. 591–594, 1998. View at Publisher · View at Google Scholar · View at PubMed
  20. D. L. Bhatt and E. J. Topol, “Scientific and therapeutic advances in antiplatelet therapy,” Nature Reviews Drug Discovery, vol. 2, no. 1, pp. 15–28, 2003. View at Publisher · View at Google Scholar · View at PubMed
  21. F. Mach, U. Schönbeck, J.-Y. Bonnefoy, J. S. Pober, and P. Libby, “Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor,” Circulation, vol. 96, no. 2, pp. 396–399, 1997. View at Google Scholar
  22. J. J. Popma, D. S. Baim, and F. S. Resnic, “Percutaneous coronary and valvular intervention,” in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, pp. 1419–1456, Saunders/Elsevier, Philadelphia, Pa, USA, 8th edition, 2008. View at Google Scholar